1.
Sudhof, T. The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature (London) (6AD).
2.
The synaptic vesicle cycle: a cascade of protein-protein interactions.
3.
Chen, K. et al. Prevention of Plasticity of Endocannabinoid Signaling Inhibits Persistent Limbic Hyperexcitability Caused by Developmental Seizures. Journal of Neuroscience 27, 46–58 (2007).
4.
Krisztina, Massa, F., Egertová, M. & Eder, M. The Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus.
5.
Nyilas, R., Dudok, B. & Urbán, G. M. Enzymatic Machinery for Endocannabinoid Biosynthesis Associated with Calcium Stores in Glutamatergic Axon Terminals.
6.
Solinas, M., Goldberg, S. R. & Piomelli, D. The endocannabinoid system in brain reward processes. British Journal of Pharmacology 154, 369–383 (2009).
7.
The endocannabinoid system in brain reward processes.
8.
Arendt, T. Alzheimer’s disease as a disorder of mechanisms underlying structural brain self-organization.
9.
Arendt, T. Alzheimer’s disease as a disorder of mechanisms underlying structural brain self-organization.
10.
Dominguez, I. D. & Strooper, B. D. Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer’s disease.
11.
Bezard, E., Brotchie, J. M. & Gross, C. E. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies : Article : Nature Reviews Neuroscience.
12.
McMurray, C. T. Huntington’s disease: new hope for therapeutics.
13.
De Keyser, J., Sulter, G. & Luiten, P. G. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?
14.
Zhu, H. L., Luo, W. Q. & Wang, H. Iptakalim protects against hypoxic brain injury through multiple pathways associated with ATP-sensitive potassium channels.
15.
Fredrik Jarskog, L., Miyamoto, S. & Lieberman, J. A. Schizophrenia: New Pathological Insights and Therapies - Annual Review of Medicine, 58(1):49.
16.
Iritani, S. Neuropathology of schizophrenia: A mini review. Neuropathology 27, 604–608 (2007).
17.
LARUELLE, M., KEGELES, L. S. & ABI-DARGHAM, A. Glutamate, Dopamine, and Schizophrenia. Annals of the New York Academy of Sciences 1003, 138–158 (2003).
18.
Torrey, E. F. et al. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biological Psychiatry 57, 252–260 (2005).
19.
Löscher, W. Current status and future directions in the pharmacotherapy of epilepsy.
20.
Mulley, J. C., Scheffer, I. E., Petrou, S. & Berkovic, S. F. Channelopathies as a genetic cause of epilepsy.
21.
Mulley, J. C., Scheffer, I. E., Petrou, S. & Berkovic, S. F. Channelopathies as a genetic cause of epilepsy.
22.
Maalouf, M., Rho, J. M. & Mattson, M. P. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies.
23.
Schmitz, B., Montouris, G., Schäuble, B. & Caleo, S. Assessing the unmet treatment need in partial-onset epilepsy: Looking beyond seizure control. Epilepsia 51, 2231–2240 (2010).
24.
Nestler, E. J. Is there a common molecular pathway for addiction? : Article : Nature Neuroscience.
25.
Dackis, C. & O’Brien, C. Neurobiology of addiction: treatment and public policy ramifications : Article : Nature Neuroscience.
26.
Volkow, N. D., Fowler, J. S. & Wang, G.-J. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies.